Plain-English translation of NCT05124457 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a long-acting insulin medication, works better than the standard for pregnant women with diabetes. Both medications help control blood sugar, but researchers want to see if detemir causes fewer episodes of dangerously low blood sugar while keeping blood sugar levels steady during pregnancy.
Uncontrolled diabetes during pregnancy can cause serious complications for both mother and baby, including premature delivery, high blood pressure, and problems for the newborn. While this medication is already approved for type 1 diabetes in pregnancy, it hasn't been fully studied in pregnant women with type 2 diabetes or gestational diabetes, so researchers want to compare it fairly to the currently standard treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either or NPH insulin to manage your blood sugar throughout your pregnancy. You'll attend regular clinic visits where your blood sugar will be monitored and your insulin dose adjusted as needed. The study will track how well each medication works and any side effects, with particular attention to low blood sugar episodes and outcomes for you and your baby.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of California, Los Angeles
Enrollment target
~336 participants
Started
February 2022
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michael Richley, MD
University of California, Los Angeles
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.